Latest Financial Results
Q2 2017
Quarter Ended Jun 30, 2017
Sign up for Email Alerts
Sign up todayStock Information
Syros Pharmaceuticals, Inc.
Symbol
NASDAQ: SYRSPrice
Change
Volume
52 week Low/High
Day Low/High
Company Overview
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros' lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.
Latest Presentation
IR Contact Information
Investor Relations
Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com
Transfer Agent
Computershare Trust Company, N.A.